Screener
Bristol-Myers Squibb BMY Impairment Charges
Impairment Charges at other companies
Other financials
Where this comes from
Reported directly by Bristol-Myers Squibb in its filing.
Tagged under the XBRL concept us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf.
The source filing: Bristol-Myers Squibb’s 10-Q, filed October 30, 2025.
- Filed
- Oct 30, 2025
- Fiscal quarter
- Q3 FY2025
- Calendar quarter
- Q3 2025
- Accession
- 0000014272-25-000149
| Line item | Nine Months Ended September 30, 2025 | Nine Months Ended September 30, 2024 |
|---|---|---|
| Depreciation and amortization, net | 3,034 | 7,720 |
| Deferred income taxes | (573) | (1,298) |
| Stock-based compensation | 420 | 387 |
| Impairment charges | 514 | 1,010 |
| Divestiture gains and royalties | (880) | (838) |
| Acquired IPRD | 2,328 | 13,343 |
| Equity investment (gains)/losses, net | (90) | (221) |
| Contingent consideration fair value adjustments | 336 | — |
Item 1. FINANCIAL STATEMENTS
FAQ
- What is Bristol-Myers Squibb's impairment charges?
- Bristol-Myers Squibb (BMY) reported impairment charges of $196M in Q3 2025.
- How has Bristol-Myers Squibb's impairment charges changed year-over-year?
- Bristol-Myers Squibb's impairment charges increased by 41.0% year-over-year, from $139M to $196M.
- What is the long-term trend for Bristol-Myers Squibb's impairment charges?
- Over 3 years (2021 to 2024), Bristol-Myers Squibb's impairment charges has grown at a 34.9% compound annual growth rate (CAGR), from $1.21B to $2.96B.
- What does impairment charges mean?
- Non-cash asset impairment charges added back in the operating cash flow reconciliation since they don't represent cash outflows.
Ask your AI about Bristol-Myers Squibb's impairment charges.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude